Literature DB >> 20452378

Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.

Christopher H Logue1, Aaron T Phillips, Eric C Mossel, Jeremy P Ledermann, Thomas Welte, Steve W Dow, Ken E Olson, Ann M Powers.   

Abstract

Having recently characterized a CD-1 outbred mouse model of pathogenesis for Western equine encephalitis virus, we examined the possible protective effects of cationic liposome-DNA complexes (CLDCs) against encephalitic arboviral infection. In this investigation, mice were pre-treated, co-treated, or post-treated with CLDC then challenged with a subcutaneous or aerosol dose of the highly virulent WEEV-McMillan strain, lethal in mice 4-5 days after inoculation. Pre-treatment with CLDCs provided a significant protective effect in mice, which was reflected in significantly increased survival rates. Further, in some instances a therapeutic effect of CLDC administration up to 12h after WEEV challenge was observed. Mice treated with CLDC had significantly increased serum IFN-gamma, TNF-alpha, and IL-12, suggesting a strong Th1-biased antiviral activation of the innate immune system. In virus-infected animals, large increases in production of IFN-gamma, TNF-alpha, MCP-1, IL-12, and IL-10 in the brain were observed by 72h after infection, consistent with neuroinvasion and viral replication in the CNS. These results indicate that strong non-specific activation of innate immunity with an immune therapeutic such as CLDC is capable of eliciting significant protective immunity against a rapidly lethal strain of WEEV and suggest a possible prophylactic option for exposed individuals. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452378      PMCID: PMC3568752          DOI: 10.1016/j.antiviral.2010.04.013

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  51 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth.

Authors:  M Whitmore; S Li; L Huang
Journal:  Gene Ther       Date:  1999-11       Impact factor: 5.250

3.  Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.

Authors:  M Lanuti; S Rudginsky; S D Force; E S Lambright; W M Siders; M Y Chang; K M Amin; L R Kaiser; R K Scheule; S M Albelda
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

4.  Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling.

Authors:  Rebeca Burdeinick-Kerr; Dhanasekaran Govindarajan; Diane E Griffin
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

5.  PKR acts early in infection to suppress Semliki Forest virus production and strongly enhances the type I interferon response.

Authors:  Gerald Barry; Lucy Breakwell; Rennos Fragkoudis; Ghassem Attarzadeh-Yazdi; Julio Rodriguez-Andres; Alain Kohl; John K Fazakerley
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

6.  Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice.

Authors:  John D Morrey; Neil E Motter; Brandon Taro; Marla Lay; Jeffery Fairman
Journal:  Antiviral Res       Date:  2008-02-25       Impact factor: 5.970

7.  Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Jane E Strasser; Nicholas Farley; Claudia Chalk; Marla Lay; Jeff Fairman
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

8.  Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study.

Authors:  Jeff Fairman; Joseph Moore; Mathieu Lemieux; Koen Van Rompay; Yongzhi Geng; John Warner; Kristina Abel
Journal:  Hum Vaccin       Date:  2009-03-14

9.  Virulence variation among isolates of western equine encephalitis virus in an outbred mouse model.

Authors:  Christopher H Logue; Christopher F Bosio; Thomas Welte; Kimberley M Keene; Jeremy P Ledermann; Aaron Phillips; Brian J Sheahan; Dennis J Pierro; Nicole Marlenee; Aaron C Brault; Catharine M Bosio; Amber J Singh; Ann M Powers; Ken E Olson
Journal:  J Gen Virol       Date:  2009-04-29       Impact factor: 3.891

10.  Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs.

Authors:  Brian B Gowen; Jeff Fairman; Steven Dow; Ryan Troyer; Min-Hui Wong; Kie-Hoon Jung; Peter C Melby; John D Morrey
Journal:  Antiviral Res       Date:  2008-10-07       Impact factor: 5.970

View more
  10 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

3.  Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses.

Authors:  Amber B Rico; Aaron T Phillips; Tony Schountz; Donald L Jarvis; Ronald B Tjalkens; Ann M Powers; Ken E Olson
Journal:  Virology       Date:  2016-09-12       Impact factor: 3.616

4.  Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses.

Authors:  Aaron T Phillips; Tony Schountz; Ann M Toth; Amber B Rico; Donald L Jarvis; Ann M Powers; Ken E Olson
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

5.  Non-specific protection from respiratory tract infections in cattle generated by intranasal administration of an innate immune stimulant.

Authors:  William Wheat; Lyndah Chow; Vanessa Rozo; Julia Herman; Kelly Still Brooks; Aimee Colbath; Randy Hunter; Steven Dow
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240

6.  Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs.

Authors:  William Wheat; Lyndah Chow; Alana Kuzmik; Sirikul Soontararak; Jade Kurihara; Michael Lappin; Steven Dow
Journal:  BMC Vet Res       Date:  2019-09-13       Impact factor: 2.741

7.  Activation of upper respiratory tract mucosal innate immune responses in cats by liposomal toll-like receptor ligand complexes delivered topically.

Authors:  William Wheat; Lyndah Chow; Jonathan Coy; Elena Contreras; Michael Lappin; Steven Dow
Journal:  J Vet Intern Med       Date:  2019-02-15       Impact factor: 3.333

8.  Evaluation of liposome toll-like receptor ligand complexes for non-specific mucosal immunoprotection from feline herpesvirus-1 infection.

Authors:  Elena T Contreras; Francisco Olea-Popelka; William Wheat; Steven Dow; Jennifer Hawley; Michael R Lappin
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

9.  Bioluminescent imaging and histopathologic characterization of WEEV neuroinvasion in outbred CD-1 mice.

Authors:  Aaron T Phillips; Charles B Stauft; Tawfik A Aboellail; Ann M Toth; Donald L Jarvis; Ann M Powers; Ken E Olson
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

10.  Human-like antibodies neutralizing Western equine encephalitis virus.

Authors:  Birgit Hülseweh; Torsten Rülker; Thibaut Pelat; Claudia Langermann; Andrè Frenzel; Thomas Schirrmann; Stefan Dübel; Philippe Thullier; Michael Hust
Journal:  MAbs       Date:  2014-02-11       Impact factor: 5.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.